Search
TScan Therapeutics Inc
TCRXAdd to Watchlist
1.070USD
-0.000-0.01%
Market hours （ET）Quotes delayed by 15 min
60.88MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+21.47%
1 Month
+5.94%
6 Months
+7.00%
Year to Date
+7.00%
1 Year
-25.17%
Key Figures
1.080Open
1.080High
103.05KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.18%Turnover Ratio
1.070Prev. Close
1.045Low
81.18KTurnover
LossP/E Static
0.49P/B
0.00%Div Yield TTM
-46.50%ROA
2.57052wk High
0.72Volume Ratio
-127.50MNet Profit
56.90MShares
-0.9574EPS TTM
1.04Beta
-80.95%ROE
0.88252wk Low
3.31%Amplitude
100.00%Gross Margin
60.88MMarket Cap
1.92Reward/Risk
4.79%Risk Rate
TradingKey Stock Score of TScan Therapeutics Inc
Currency: USD Updated: 2026-07-01Key Insights
TScan Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 161 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
TScan Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
TScan Therapeutics Inc Highlights
StrengthsRisks
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.32M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 10.32M.
Overvalued
The company’s latest PE is -1.12, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 36.25M shares, decreasing 31.67% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.12.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
6.000
Target Price
+512.18%
Upside Space
TScan Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
TScan Therapeutics Inc Info
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Ticker SymbolTCRX
CompanyTScan Therapeutics Inc
CEOMacbeath (Gavin)
Websitehttps://www.tscan.com
Related Instruments
+2.20%
+1.44%
+4.87%
+2.08%
+1.94%
+3.41%
+2.55%
+3.73%
+2.86%
+2.01%
+3.92%
+1.89%
+3.74%
+3.33%
+1.48%
0.00%
+2.54%
+4.03%
+0.60%
+4.23%Popular Instruments
52755.400
+501.100 (+0.96%)
29700.400
-98.900 (-0.33%)
7515.200
+39.700 (+0.53%)
14841.000
-514.000 (-3.35%)
68889.000
-596.000 (-0.86%)
6375.900
+100.500 (+1.60%)
67.564
-0.404 (-0.59%)
304.855
+10.475 (+3.56%)
198.930
+1.350 (+0.68%)
4119.880
+89.110 (+2.21%)
FAQs
What is the current price of TScan Therapeutics Inc (TCRX)?
The current price of TScan Therapeutics Inc (TCRX) is 1.07.
What is the symbol of TScan Therapeutics Inc?
The ticker symbol of TScan Therapeutics Inc is TCRX.
What is the 52-week high of TScan Therapeutics Inc?
The 52-week high of TScan Therapeutics Inc is 2.57.
What is the 52-week low of TScan Therapeutics Inc?
The 52-week low of TScan Therapeutics Inc is 0.88.
What is the market capitalization of TScan Therapeutics Inc?
The market capitalization of TScan Therapeutics Inc is 69.93M.
Is TScan Therapeutics Inc (TCRX) currently rated as Buy, Hold, or Sell?
According to analysts, TScan Therapeutics Inc (TCRX) has an overall rating of Buy, with a price target of 6.00.
What is the Earnings Per Share (EPS TTM) of TScan Therapeutics Inc (TCRX)?
The Earnings Per Share (EPS TTM) of TScan Therapeutics Inc (TCRX) is -1.00.